Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Priority Review
Indication
KEYTRUDA (pembrolizumab) in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1 (CPS≥10) as determined by a validated test.
Therapeutic area
Oncology